Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pulmonary Artery Catheters May Improve Heart Failure Quality Of Life

This article was originally published in The Gray Sheet

Executive Summary

Pulmonary artery catheterization (PAC) of severe heart failure patients is not associated with lower mortality, although it may assist doctors in improving patient quality of life, according to ESCAPE trial findings

You may also be interested in...



Pulmonary catheter study proposals to be reviewed by NHLBI advisory board Sept. 4.

PULMONARY ARTERY CATHETER RESEARCH PROPOSALS TO BE REVIEWED BY NHLBI advisory board on Sept. 4. The National Heart, Lung and Blood Institute's advisory panel is slated to review research proposals developed at an Aug. 25-26 workshop in Alexandria, Virginia sponsored by FDA and the National Institutes of Health to address questions about the safety and effectiveness of pulmonary artery catheters.

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel